PPARA and Hyperglycemia: Consistent with the above-mentioned studies, current results indicate that ALS-L1023 treatment may induce weight loss and decrease hepatic lipid accumulation in part through hepatic PPARα activation and that reduced hepatic lipids seem to alleviate insulin resistance and hyperglycemia in ALS-L1023-treated obese mice.